Posted BY: | NwoReport
The FDA recently granted approval and emergency use authorization (EUA) for the latest COVID-19 vaccines from Pfizer and Moderna. However, the public response has been overwhelmingly negative, with concerns about lacking human clinical trials to support these approvals.
Newsweek, a publication known for its stance on vaccination, has criticized the FDA for approving these vaccines without clinical trials involving humans. The newly approved “booster” shots, as they are called, underwent testing on just eight mice, which has raised serious questions about the validity of the scientific process.
Newsweek’s Nick Mordowanec highlighted the absence of human involvement in the clinical trials, leading to doubts about the vaccines’ efficacy. This development has sparked a debate about the FDA’s decision-making process and the speed at which these vaccines have been approved.
The FDA’s request for Pfizer and Moderna to develop these new vaccines stemmed from concerns about potential fall season variants of COVID-19 that existing vaccines might not cover. This decision was made despite acknowledging that COVID, like common cold coronaviruses, will likely persist.
Dr. Mandy Cohen, director of the CDC, emphasized the need for ongoing vaccine development to combat evolving virus variants. She argued that vaccine updates become necessary as the virus changes over time, even for individuals who have previously been infected.
FDA Commissioner Dr. Robert Califf defended the decision to skip human clinical trials for the new vaccines, citing the agency’s experience reviewing strain changes in vaccines like the annual flu shot.
The controversy surrounding these new COVID vaccines has led to debates about their safety and efficacy. Some hospital systems have even attempted to mandate their administration.
In conclusion, the FDA’s approval of the latest COVID vaccines without human clinical trials has raised significant concerns and skepticism. The debate over the necessity and safety of these vaccines continues as health officials grapple with evolving variants of the virus.